Analyst Jeet Mukherjee of BTIG maintained a Buy rating on Kymera Therapeutics, retaining the price target of $59.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jeet Mukherjee has given his Buy rating due to a combination of factors that highlight the potential of Kymera Therapeutics. The company’s decision to add a second dose to the Phase 1b study of their STAT6 degrader, KT-621, in atopic dermatitis patients is seen as a strategic move. This choice is based on the rapid enrollment in the study, which allows for a more comprehensive evaluation of dose efficacy and safety, optimizing the chances for success in future stages of development. The anticipated results from this study in the fourth quarter of 2025 are expected to be a significant catalyst for the stock, especially if the outcomes align with those of existing treatments like Dupixent.
Furthermore, Kymera’s strong financial position, with a substantial cash reserve, provides a solid foundation for ongoing and future research endeavors. The company’s proactive approach in having a next-generation molecule ready for all programs, including a follow-on STAT6 degrader, demonstrates their commitment to innovation and long-term growth. These factors, combined with promising preclinical data for their new degrader targeting IRF5, contribute to Mukherjee’s optimistic outlook and Buy rating for Kymera Therapeutics.
KYMR’s price has also changed slightly for the past six months – from $34.410 to $37.680, which is a 9.50% increase.